Phoenix Bio



DMPK & Toxicology

Comparison of the hepatic effects of phenobarbital in chimeric mice containing either
rat or human hepatocytes with humanized constitutive androstane receptor (CAR) and
pregnane X receptor (PXR) mice (hCAR/hPXR mice).
Yamada, et. al.(住友化学株式会社)
Toxicological Science, kfaa125
Chimeric mice with humanized livers demonstrate human-specific hepatotoxicity caused by a therapeutic antibody against TRAIL-receptor 2/death receptor 5
Nihira, K. Nan-Ya, K. I. Kakuni, M. Ono, Y. Yoshikawa, Y. Ota, T. Hiura, M. Yoshinari, K.
Toxicol Sci. 2019 Jan 1;167(1):190-201.
Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion
Takehara,I. Watanabe,N. Mori,D. Ando,O. Kusuhara,H.
J Pharm Sci. 2019 Mar 21.
Chimeric mice with human hepatocytes: A new system for genotoxicity studies
Tateno, C. Fukumuro, M. Masumori, S. Kakuni, M. Ishida, Y. Shimada, T. Hayashi, M.
Mutat Res. 2019 Mar;839:9-12.
The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice
de la Rosa Rodriguez, M. A. Sugahara, G. Hooiveld, Gjej Ishida, Y. Tateno, C. Kersten, S.
BMC Genomics. 2018 Jun 7;19(1):443
Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver
Sanoh, S. Yamachika, Y. Tamura, Y. Kotake, Y. Yoshizane, Y. Ishida, Y. Tateno, C. Ohta, S.
J Toxicol Sci. 2017;42(5):589-96
Evaluation of the human relevance of the constitutive androstane receptor-mediated mode of action for rat hepatocellular tumor formation by the synthetic pyrethroid momfluorothrin
Okuda, Y. Kushida, M. Kikumoto, H. Nakamura, Y. Higuchi, H. Kawamura, S. Cohen, S. M. Lake, B. G. Yamada, T.
J Toxicol Sci. 2017;42(6):773-88
Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice
Ohara A , Takahashi Y,  Kondo  M,  Okuda Y, Takeda  S,  Kushida M, Kobayashi  K,  Sumida K, Yamada T
Toxicol Res (Camb). 2017 Aug 24;6(6):795-813
Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis
Toyoda, Y. Takada, T. Suzuki, H.
Sci Rep. 2016 Apr 18;6:24586
Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver
Yamazaki, Hiroshi, Kuribayashi, Shunji Inoue, Tae Honda, Tomohiro Tateno, Chise Oofusa, Ken Ninomiya, Shinichi Ikeda, ToshihikoIzumi, Takashi Horie, Toru
Toxicol. Res. ,2015, 4:106–11
Chimeric Mice with Hepatocyte-humanized Liver as an Appropriate Model to Study Human Peroxisome Proliferator-activated Receptor-alpha
Tateno, C. Yamamoto, T. Utoh, R. Yamasaki, C. Ishida, Y. Myoken, Y. Oofusa, K. Okada, M. Tsutsui, N. Yoshizato, K.
Toxicol Pathol. 2015 Feb;43(2):233-48
Human Hepatocytes Support the Hypertrophic but not the Hyperplastic Response to the Murine Nongenotoxic Hepatocarcinogen Sodium Phenobarbital in an In Vivo Study Using a Chimeric Mouse with Humanized Liver
Yamada, T. Okuda, Y. Kushida, M. Sumida, K. Takeuchi, H. Nagahori, H. Fukuda, T. Lake, B. G. Cohen, S. M. Kawamura, S.
Toxicol Sci. 2014 Nov;142(1):137-57
Endogenous and xenobiotic metabolite profiling of liver extracts from SCID and chimeric humanized mice following repeated oral administration of troglitazone
Barnes, A. J. Baker, D. R. Hobby, K. Ashton, S. Michopoulos, F. Spagou, K.Loftus, N. J. Wilson, I. D.
Xenobiotica. 2014 Jan;44(2):174-85
Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers
Schulz-Utermoehl, T. Sarda, S. Foster, J. R. Jacobsen, M. Kenna, J. G. Morikawa, Y. Salmu, J. Gross, G. Wilson, I. D.
Xenobiotica. 2012 Jun;42(6):503-17
Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury
Kakuni, M. Morita, M. Matsuo, K. Katoh, Y. Nakajima, M. Tateno, C. Yokoi, T.
Toxicol Lett. 2012 Oct 2;214(1):9-18



Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized

TK-NOG mouse.

Maki Miyamoto, et. al.(武田薬品工業株式会社)
Xenobiotica. 2020 Aug 25; 1-10.  doi:10.1080/00498254.2020.1808735
Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation
Steeneck, C. Kinzel, O. Anderhub, S. Hornberger, M. Pinto, S. Morschhaeuser, B. Braun, F. Kleymann, G. Hoffmann, T.
ACS Med Chem Lett. 2020 Jan 27;11(2):179-187. doi: 10.1021/acsmedchemlett.9b00572. eCollection 2020 Feb 13.
Predictability of human pharmacokinetics of drugs that undergo hepatic organic anion transporting polypeptide (OATP)-mediated transport using single-species allometric scaling in chimeric mice with humanized liver: Integration with hepatic drug metabolism
Sanoh, S. Naritomi, Y. Kitamura, S. Shinagawa, A. Kakuni, M. Tateno, C. Ohta, S.
Xenobiotica. 2020 Jun 5:1-10. doi: 10.1080/00498254.2020.1769229.
Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver
Miyamoto, M. Iwasaki, S. Chisaki, I. Nakagawa, S. Amano, N. Kosugi, Y. Hirabayashi, H.
Xenobiotica. 2019 Dec;49(12):1379-1387.
Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver
Sanoh, S. Tamura, Y. Fujino, C. Sugahara, G. Yoshizane, Y. Yanagi, A. Kisoh, K. Ishida, Y. Tateno, C. Ohta, S. Kotake, Y.
Biol Pharm Bull. 2019;42(8):1366-1375.
Changes in Bile Acid Concentrations in Chimeric Mice Transplanted with Different Replacement Indexes of Human Hepatocytes
Fujino C, Sanoh S,* Tamura Y, Ishida Y, Tateno C, Ohta S and  Kotakea Y
BPB Reports 2, 29-34 (2019)
Organic anion transporting polypeptides (OATPs)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver
Uchida, M. Tajima, Y. Kakuni, M. Kageyama, Y. Okada, T. Sakudara, E. Tateno, C. Hayashi, R.
Drug Metab Dispos. 2018 Jan;46(1):11-19.
Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions
Takaoka, N. Sanoh, S. Okuda, K. Kotake, Y. Sugahara, G. Yanagi, A. Ishida, Y. Tateno, C. Tayama, Y. Sugihara, K. Kitamura, S. Kurosaki, M. Terao, M. Garattini, E. Ohta, S.
Biochem Pharmacol. 2018 Aug;154:28-38
FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver
Papazyan, R. Liu, X. Liu, J. Dong, B. Plummer, E. M. Lewis, R. D., 2nd Roth, J. D. Young, M. A.
J Lipid Res. 2018 Jun;59(6):982-93
Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver
Miyamoto, M. Iwasaki, S.  Chisaki, I. Nakagawa, S. Amano, N. Hirabayashi, H.
Xenobiotica. 2017 Dec;47(12):1052-63
Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans
Nakada, N. Kawamura, A. Kamimura, H. Sato, K. Kazuki, Y. Kakuni, M. Ohbuchi, M. Kato, K. Tateno, C. Oshimura, M. Usui, T.
Biopharm Drug Dispos. 2016 Jan;37(1):3-14
Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver
Kato, K. Ohbuchi, M. Hamamura, S. Ohshita, H. Kazuki, Y. Oshimura, M. Sato, K. Nakada, N. Kawamura, A. Usui, T. Kamimura, H. Tateno, C.
Drug Metab Dispos. 2015 Aug;43(8):1208-17
Application of Chimeric Mice with Humanized Liver for Study of Human-Specific Drug Metabolism
Bateman, T. Reddy, V. B. Kakuni, M. Morikawa, Y. Kumar, S.
Drug Metab Dispos. 2014 Jun;42(6):1055-65
Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS
Ohtsuki, S. Kawakami, H. Inoue, T. Nakamura, K. Tateno, C. Katsukura, Y. Obuchi, W. Uchida, Y. Kamiie, J. Horie, T. Terasaki, T.
Drug Metab Dispos June 2014 42:1039-43
Prediction of human metabolism of FK3453 by aldehyde oxidase using chimeric mice transplanted with human or rat hepatocytes
Sanoh, S. Nozaki, K. Murai, H. Terashita, S. Teramura, T. Ohta, S.
Drug Metab Dispos. 2012 Jan;40(1):76-82
Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers
Samuelsson, K. Pickup, K. Sarda, S. Swales, J. G. Morikawa, Y. Schulz-Utermoehl, T. Hutchison, M. Wilson, I. D.
Xenobiotica. 2012 Nov;42(11):1128-37
Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver
Hasegawa, M. Tahara, H. Inoue, R. Kakuni, M. Tateno, C. Ushiki, J.
Drug Metab Dispos. 2012 Mar;40(3):474-80.
Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism
De Serres, M. Bowers, G. Boyle, G. Beaumont, C. Castellino, S. Sigafoos, J. Dave, M. Roberts, A. Shah, V. Olson, K. Patel, D. Wagner, D. Yeager, R. Serabjit-Singh, C.
Xenobiotica. 2011 Jun;41(6):464-75
Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice
Shoda, J. Okada, K. Inada, Y. Kusama, H. Utsunomiya, H. Oda, K. Yokoi, T. Yoshizato, K. Suzuki, H.
Hepatol Res. 2007 Jul;37(7):548-56
Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver
Nishimura, M. Yoshitsugu, H. Yokoi, T. Tateno, C. Kataoka, M. Horie, T. Yoshizato, K. Naito, S.
Xenobiotica. 2005 Sep;35(9):877-90
In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver
Katoh, M. Matsui, T. Nakajima, M. Tateno, C. Soeno, Y. Horie, T. Iwasaki, K. Yoshizato, K. Yokoi, T.
Drug Metab Dispos. 2005 Jun;33(6):754-63
Expression of human phase II enzymes in chimeric mice with humanized liver
Katoh, M. Matsui, T. Okumura, H. Nakajima, M. Nishimura, M. Naito, S.Tateno, C. Yoshizato, K. Yokoi, T.
Drug Metab Dispos. 2005 Sep;33(9):1333-40
Near completely humanized liver in mice shows human-type metabolic responses to drugs
Tateno, C. Yoshizane, Y. Saito, N. Kataoka, M. Utoh, R. Yamasaki, C. Tachibana, A. Soeno, Y. Asahina, K. Hino, H. Asahara, T. Yokoi, T. Furukawa, T. Yoshizato, K.
Am J Pathol. 2004 Sep;165(3):901-12.



Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection
Cheng,X. Uchida,T.Xia,Y. Umarova R. Liu,C. J. Chen,P. J.Gaggar,A. Suri,V. Mucke,M. M. Vermehren,J. Zeuzem,S. Teraoka,Y. Osawa,M. Aikata,H. Tsuji,K. Mori,N. Hige,S. Karino,Y. Imamura,M. Chayama,K. Liang,T.J.
J Clin Invest. 2020 Mar 12. pii: 135616. doi: 10.1172/JCI135616.
An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People
Hayashi, S. Khan, A. Simons, B. C. Homan, C. Matsui, T. Ogawa, K. Kawashima, K. Murakami, S. Takahashi, S. Isogawa, M. Ikeo, K. Mizokami, M. McMahon, B. J. Tanaka, Y.
Hepatology. 2019 Jan;69(1):19-33.
CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients
Nomura, M. Tsuge, M. Uchida, T. Hiraga, N. Kurihara, M. Tsushima, K. Fujino, H. Nakahara, T. Murakami, E. Abe-Chayama, H. Kawaoka, T. Miki, D. Hiramatsu, A. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Zhang, Y. Makokha, G. N. Hayes, C. N. Tanaka, S. Chayama, K.
J Viral Hepat. 2018 Jul 11.
ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection
Thi, E. P. Dhillon, A. P. Ardzinski, A. Bidirici-Ertekin, L. Cobarrubias, K. D. Cuconati, A. Kondratowicz, A. S. Kwak, K. Li, A. H. L. Miller, A. Pasetka, C. Pei, L.Phelps, J. R. Snead, N. M. Wang, X. Ye, X. Sofia, M. J. Lee, A. C. H.
Gastroenterology. 2018 Feb;154(3):652-662
Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection
Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.
Gastroenterology. 2018 Feb;154(3):652-662
Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics
Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.
Hepatology. 2018 Aug;68(2):473-484
Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers
Furuta, M. Tanaka, H. Shiraishi, Y. Unida, T. mamura, M. Fujimoto, A. Fujita, M. Sasaki-Oku, A. Maejima, K. Nakano, K. Kawakami, Y. Arihiro, K. Aikata, H. Ueno, M. Hayami, S. Ariizumi, S. I. Yamamoto, M. Gotoh, K. Ohdan, H. Yamaue, H. Miyano, S. Chayama, K. Nakagawa, H.
Oncotarget. 2018 May 18;9(38):25075-25088.
Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus
Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T. Chayama, K.
Antimicrob Agents Chemother. 2017 May 24;61(6).
The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection
Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.
PLoS One. 2017 Jan 17;12(1):e0169648
A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression
Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.
J Hepatol. 2018 Mar;68(3):412-420
Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages
Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.
Hepatology. 2017 Dec;66(6):1779-1793
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection
Tsuge, M. Hiraga, N. Uchida, T. Kan, H. Miyaki, E. Masaki, K. Ono, A. Nakahara, T. Abe-Chayama, H. Zhang, Y. Naswa, M. G. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Chayama, K.
J Gastroenterol. 2016 Nov;51(11):1073-1080
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Decorsiere, A. Mueller, H. van Breugel, P. C. Abdul, F. Gerossier, L. Beran, R. K. Livingston, C. M. Niu, C. Fletcher, S. P. Hantz, O. Strubin, M.
Nature. 2016 Mar 17;531(7594):386-9
Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice
Komatsu, H. Inui, A. Murano, T. Tsunoda, T. Sogo, T. Fujisawa, T.
BMC Res Notes. 2015 Aug 20;8:366
HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice
Tsuge, M. Hiraga, N. Akiyama, R. Tanaka, S. Matsushita, M. Mitsui, F. Abe, H. Kitamura, S. Hatakeyama, T. Kimura, T. Miki, D. Mori, N. Imamura, M. Takahashi, S. Hayes, C. N. Chayama, K.
J Gen Virol. 2010 Jul;91(Pt 7):1854-64.



Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir
Wang, T. Babusis, D. Park, Y. Niu, C. Kim, C. Zhao, X. Lu, B. Ma, B. Muench, R. C. Sperger, D. Ray, A. S. Murakami, E.
Drug Metab Pharmacokinet. 2020 Jun;35(3):334-340. doi: 10.1016/j.dmpk.2020.04.333. Epub 2020 Apr 16.
Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development
Lupberger, J. Croonenborghs, T. Roca Suarez, A. A. Van Renne, N. Juhling, F. Oudot, M. A. Virzi, A. Bandiera, S. Jamey, C. Meszaros, G. Brumaru, D. Mukherji, A. Durand, S. C. Heydmann, L. Verrier, E. R. El Saghire, H. Hamdane, N. Bartenschlager, R. Fereshetian, S. Ramberger, E. Sinha, R. Nabian, M. Everaert, C. Jovanovic, M. Mertins, P. Carr, S. A. Chayama, K. Dali-Youcef, N. Ricci, R. Bardeesy, N. M. Fujiwara, N. Gevaert, O. Zeisel, M. B. Hoshida, Y. Pochet, N. Baumert, T. F.
Gastroenterology. 2019 Aug;157(2):537-551.e9.
HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response
Hamdane, N. Juhling, F. Crouchet, E. El Saghire, H. Thumann, C. Oudot, M. A. Bandiera, S. Saviano, A. Ponsolles, C. Roca Suarez, A. A. Li, S. Fujiwara, N. Ono, A. Davidson, I. Bardeesy, N. Schmidl, C. Bock, C. Schuster, C. Lupberger, J. Habersetzer, F. Doffoel, M. Piardi, T. Sommacale, D. mamura, M. Uchida, T. Ohdan, H. Aikata, H. Chayama, K. Boldanova, T. Pessaux, P. Fuchs, B. C. Hoshida, Y. Zeisel, M. B. Duong, F. H. T. Baumert, T. F.
Gastroenterology. 2019 Jun;156(8):2313-2329.e7.
Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice
Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.
Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.
Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology
Uchida, T. Imamura, M. Kan, H. Hiraga, N. Hayes, C. N. Tsuge, M. Abe-Chayama, H. Aikata, H. Makokha, G. N. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.
J Gen Virol. 2017 May;98(5):1040-1047
Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus
Miyaki, E. Hiraga, N. Imamura, M. Uchida, T.  Kan, H.  Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Serikawa, M. Aikata, H. Ochi, H. Ishida, Y. Tateno, C. Ohdan, H. Chayama, K.
PLoS One. 2017 Mar 2;12(3):e0172412
Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus
Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.
Antiviral Res.2017 Oct;146:130-138
Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells
Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.
Hepatology. 2017 Nov;66(5):1430-1443
Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing
Kan, H. Imamura, M. Uchida, T. Hiraga, N. Hayes, C. N. Tsuge, M. Abe, H. Aikata, H. Makokha, G. N. Chowdhury, S. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.
J Infect Dis. 2016 Dec 1;214(11):1687-1694
In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus
Watanabe, T. Hatakeyama, H. Matsuda-Yasui, C. Sato, Y. Sudoh, M. Takagi, A. Hirata, Y. Ohtsuki, T. Arai, M. Inoue, K. Harashima, H. Kohara, M.
Sci Rep. 2014 Apr 23;4:4750
Hepatitis C Virus Core Protein Suppresses Mitophagy by Interacting with Parkin in the Context of Mitochondrial Depolarization
Hara, Y. Yanatori, I. Ikeda, M. Kiyokage, E. Nishina, S. Tomiyama, Y. Toida, K. Kishi, F. Kato, N. Imamura, M. Chayama, K. Hino, K.
Am J Pathol. 2014 Nov;184(11):3026-39
Hepatitis C virus kinetics by administration of pegylated interferon-alpha in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
Watanabe, T. Sugauchi, F. Tanaka, Y. Matsuura, K. Yatsuhashi, H. Murakami, S. Iijima, S. Iio, E. Sugiyama, M. Shimada, T. Kakuni, M. Kohara, M. Mizokami, M.
Gut. 2013 Sep;62(9):1340-6
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
Sainz, B., Jr. Barretto, N. Martin, D. N. Hiraga, N. Imamura, M. Hussain, S. Marsh, K. A. Yu, X. Chayama, K. Alrefai, W. A. Uprichard, S. L.
Nat Med. 2012 Jan 8;18(2):281-5
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
Lupberger, J. Zeisel, M. B. Xiao, F. Thumann, C. Fofana, I. Zona, L. Davis, C. Mee, C. J. Turek, M. Gorke, S. Royer, C. Fischer, B. Zahid, M. N. Lavillette, D. Fresquet, J. Cosset, F. L. Rothenberg, S. M. Pietschmann, T. Patel, A. H.Pessaux, P. Doffoel, M. Raffelsberger, W. Poch, O. McKeating, J. A. Brino, L. Baumert, T. F.
Nat Med. 2011 May;17(5):589-95